NYSE:CBM - Cambrex Stock Price, Forecast & News

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) posted its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. Cambrex had a net margin of 5.96% and a return on equity of 5.38%. The firm's revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 EPS. View Cambrex's Earnings History.

5 brokers have issued twelve-month target prices for Cambrex's stock. Their forecasts range from $43.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.7%. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Media coverage about CBM stock has been trending very negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cambrex earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Cambrex.

Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), NVIDIA (NVDA), Intel (INTC), Under Armour (UAA), Broadcom (AVGO) and Juno Therapeutics (JUNO).

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $59.99.

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

The official website for Cambrex is http://www.cambrex.com/.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]